• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target.新型冠状病毒肺炎（COVID-19）中微血栓的发病机制无法通过直接口服抗凝剂（DOAC）控制：中性粒细胞胞外诱捕网形成（NETosis）应成为靶点。
J Intern Med. 2021 Mar;289(3):420-421. doi: 10.1111/joim.13228. Epub 2021 Jan 10.
2
Microthrombi cause cardiac injury in COVID-19.微血栓在新冠病毒肺炎中导致心脏损伤。
Nat Rev Cardiol. 2021 May;18(5):306. doi: 10.1038/s41569-021-00524-5.
3
Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis.新冠病毒肺炎合并脑静脉血栓形成患者的抗凝治疗方法
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105222. doi: 10.1016/j.jstrokecerebrovasdis.2020.105222. Epub 2020 Aug 3.
4
COVID-19 and anticoagulant based therapeutics: Approach with great promise.2019冠状病毒病与基于抗凝剂的疗法：前景广阔的方法。
J Infect Public Health. 2021 May;14(5):681-682. doi: 10.1016/j.jiph.2020.09.014. Epub 2020 Oct 7.
5
Letter by Wong and Siu Regarding Article, "Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study".王和萧就《微血栓是新冠病毒肺炎心脏损伤的主要原因：一项病理学研究》一文所写的信。
Circulation. 2021 Aug 17;144(7):e156-e157. doi: 10.1161/CIRCULATIONAHA.121.054509. Epub 2021 Aug 16.
6
Response by Pellegrini et al to Letter Regarding Article, "Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study".佩莱格里尼等人对关于文章《微血栓是 COVID-19 心脏损伤的主要原因：一项病理学研究》的信件的回应
Circulation. 2021 Aug 17;144(7):e158-e159. doi: 10.1161/CIRCULATIONAHA.121.055585. Epub 2021 Aug 16.
7
Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from 'Spanish flu' 1918/1919 in Switzerland to Coronavirus disease 2019.SARS-CoV-2 肺内大血栓的发生率高于甲型流感：瑞士 1918/1919 年“西班牙流感”至 2019 年冠状病毒病的尸检结果。
J Pathol Clin Res. 2021 Mar;7(2):135-143. doi: 10.1002/cjp2.189. Epub 2020 Nov 13.
8
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
9
Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.在感染新型冠状病毒2的住院患者中从口服抗凝剂转换为胃肠外肝素：评论
Intern Emerg Med. 2021 Mar;16(2):517-518. doi: 10.1007/s11739-020-02358-4. Epub 2020 May 6.
10
Mechanisms of stroke and the role of anticoagulants in COVID-19.中风的机制及抗凝剂在新型冠状病毒肺炎中的作用
J Formos Med Assoc. 2020 Nov;119(11):1721-1722. doi: 10.1016/j.jfma.2020.06.026. Epub 2020 Jun 26.

引用本文的文献

1
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.精准营养以重置长期新冠病毒感染中病毒诱导的人类代谢重编程和失调（HMRD）。
NPJ Sci Food. 2024 Mar 30;8(1):19. doi: 10.1038/s41538-024-00261-2.
2
Structure-Activity Relationship of PAD4 Inhibitors and Their Role in Tumor Immunotherapy.PAD4抑制剂的构效关系及其在肿瘤免疫治疗中的作用
Pharmaceutics. 2024 Feb 28;16(3):335. doi: 10.3390/pharmaceutics16030335.
3
Efficacy and Safety of Anticoagulant Therapy in COVID-19-Related Pulmonary Embolism with Different Extension.不同范围的新型冠状病毒肺炎相关肺栓塞抗凝治疗的疗效和安全性
Biomedicines. 2023 Apr 26;11(5):1282. doi: 10.3390/biomedicines11051282.
4
Molecular mechanisms and therapeutic target of NETosis in diseases.疾病中嗜中性粒细胞胞外陷阱形成的分子机制及治疗靶点
MedComm (2020). 2022 Aug 19;3(3):e162. doi: 10.1002/mco2.162. eCollection 2022 Sep.
5
The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?直接口服抗凝剂在 COVID-19 时代的作用：抗病毒治疗和药物遗传学是限制因素吗？
Croat Med J. 2022 Jun 22;63(3):287-294. doi: 10.3325/cmj.2022.63.287.
6
The Role of Heparin in COVID-19: An Update after Two Years of Pandemics.肝素在新冠疫情中的作用：大流行两年后的最新情况
J Clin Med. 2022 May 30;11(11):3099. doi: 10.3390/jcm11113099.
7
The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: A systematic review and meta-analysis.既往口服抗凝药物使用对 COVID-19 临床结局的影响：系统评价和荟萃分析。
Am J Emerg Med. 2022 Apr;54:107-110. doi: 10.1016/j.ajem.2022.01.059. Epub 2022 Feb 3.
8
Reply to Gremese et al.: Statistical reasoning to evaluate treatment effects when data are collected with lack of design: Covid-19 experience.对格雷梅塞等人的回复：在缺乏设计的情况下收集数据时评估治疗效果的统计推理：新冠疫情的经验
Proc Natl Acad Sci U S A. 2022 Feb 15;119(7). doi: 10.1073/pnas.2103168119.
9
Inhibition of NETosis for treatment purposes: friend or foe?抑制 NETosis 用于治疗：是敌是友？
Mol Cell Biochem. 2022 Mar;477(3):673-688. doi: 10.1007/s11010-021-04315-x. Epub 2022 Jan 7.
10
Increased histone-DNA complexes and endothelial-dependent thrombin generation in severe COVID-19.严重 COVID-19 中组蛋白-DNA 复合物增加和内皮依赖性凝血酶生成。
Vascul Pharmacol. 2022 Feb;142:106950. doi: 10.1016/j.vph.2021.106950. Epub 2021 Dec 3.

本文引用的文献

1
Direct oral anticoagulant use and risk of severe COVID-19.直接口服抗凝药物的使用与严重 COVID-19 风险。
J Intern Med. 2021 Mar;289(3):411-419. doi: 10.1111/joim.13205. Epub 2020 Dec 19.
2
Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.关于“自身免疫性疾病患者中新型冠状病毒肺炎的患病率及临床结局：一项系统评价与荟萃分析”的通信
Ann Rheum Dis. 2023 Jan;82(1):e5. doi: 10.1136/annrheumdis-2020-219309. Epub 2020 Nov 3.
3
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study.COVID-19 相关性急性呼吸窘迫综合征的病理生理学：一项多中心前瞻性观察研究。
Lancet Respir Med. 2020 Dec;8(12):1201-1208. doi: 10.1016/S2213-2600(20)30370-2. Epub 2020 Aug 27.
4
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome.中性粒细胞胞外诱捕网在新冠病毒疾病急性呼吸窘迫综合征的免疫性血栓形成中发挥作用。
Blood. 2020 Sep 3;136(10):1169-1179. doi: 10.1182/blood.2020007008.
5
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.意大利北部一系列 COVID-19 病例的肺脏尸检结果：一项两中心描述性研究。
Lancet Infect Dis. 2020 Oct;20(10):1135-1140. doi: 10.1016/S1473-3099(20)30434-5. Epub 2020 Jun 8.
6
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT.与新型冠状病毒肺炎相关的低氧血症：双能CT上的血管和灌注异常
Lancet Infect Dis. 2020 Dec;20(12):1365-1366. doi: 10.1016/S1473-3099(20)30367-4. Epub 2020 Apr 30.
7
Targeting potential drivers of COVID-19: Neutrophil extracellular traps.靶向 COVID-19 的潜在驱动因素：中性粒细胞胞外陷阱。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200652.

The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target.

作者信息

Gremese E, Ferraccioli G

机构信息

From the, Rheumatology, Department of Medicine, FPG, UCSC, Rome, Italy.

出版信息

J Intern Med. 2021 Mar;289(3):420-421. doi: 10.1111/joim.13228. Epub 2021 Jan 10.

DOI:10.1111/joim.13228
PMID:33423337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8014777/
Abstract
摘要